Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | PARL | Q9H300 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2258736 | 0.94 | KMT2A (0.46) | MAPK1KMT2ASMN1; SMN2ALOX12PARL | |
| Ether SCHEMBL1205236 | 0.89 | ALOX12 (0.42) | MAPK1KMT2ASMN1; SMN2ALOX12PARL | |
| SCHEMBL12109362 | 0.83 | LMNA (0.47) | KMT2ASMN1; SMN2GLAGAAATM | |
| SCHEMBL12422042 | 0.83 | POLB (0.50) | KMT2ASMN1; SMN2HPGDGLAPOLB | |
| SCHEMBL2581766 | 0.81 | KMT2A (0.43) | MAPK1KMT2AHPGDPOLBGAA | |
| SCHEMBL13448336 | 0.80 | KMT2A (0.45) | KMT2ASMN1; SMN2HPGDGLAPOLB | |
| SCHEMBL2607958 | 0.80 | GLA (0.46) | KMT2ASMN1; SMN2HPGDGLAPOLB | |
| SCHEMBL12414360 | 0.80 | GLA (0.43) | MAPK1KMT2ASMN1; SMN2HPGDMGLL | |
| SCHEMBL7109646 | 0.80 | PARP10 (0.46) | KMT2AGLAALDH1A1 | |
| SCHEMBL406877 | 0.80 | KMT2A (0.52) | KMT2ASMN1; SMN2HPGDGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110982-A | Preparation method of protein fixed-point pegylation modification | 科兴生物制药股份有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-103193879-A | Preparation method for poly(ethylene glycol) modified recombinant human interleukin-2 | SHENZHEN YATAIXING INDUSTRY LTD | 2013-07-10 | — | — | CN | claimed |
| CN-118265711-A | Chromanamidine monocyclic lactam antibiotics | 默沙东有限责任公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4168424-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11401379-B2 | Oraganocarbonate-modified prepolymer, its use as a reactant for the preparation of isocyanate-free and isothiocyanate-free alkoxysilane polymers, and compositions thereof | MERZ+BENTELI AG (CH) | 2022-08-02 | — | — | US | disclosed |
| CN-1764456-A | Treatment of related diseases using full alpha-7 nACh receptor agonists | PHARMACIA & UPJOHN CO LLC (US) | 2006-04-26 | — | — | CN | disclosed |
| EP-0688314-B1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AG (DE) | 2001-10-04 | — | — | EP | disclosed |
| US-5965770-A | CHIRAL PURITY; SYNTHETIC PEPTIDES USED AS REAGENTS FOR ANALYTICAL TESTS, SWEETENING AGENTS, SYNTHETIC HORMONES | SOLVAY (BE) | 1999-10-12 | — | — | US | disclosed |
| US-5804559-A | WATER SOLUBILITY | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-09-08 | — | — | US | disclosed |
| US-5770692-A | METHOD OF INTRODUCING UREIDO GROUPS INTO PEPTIDES WHILE PRESERVING STEREOCHEMISTRY | PEPTISYNTHA (BE) | 1998-06-23 | — | — | US | disclosed |
| EP-0562659-B1 | Process to synthetise peptides and new intermediates thereof | SOLVAY (BE) | 1997-12-17 | — | — | EP | disclosed |
| EP-0688314-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994021604-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-09-29 | — | — | WO | disclosed |
| EP-0562659-A1 | Process to synthetise peptides and new intermediates thereof | SOLVAY (Société Anonyme) (BE) | 1993-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | MAPK1 2602/4885KMT2A 2943/4885SMN1; SMN2 1997/4885 |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | PITRM1, NME4, PDF | MAPK1 3923/4885KMT2A 4556/4885SMN1; SMN2 1175/4885 |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | ARG2, NLN, OAT | MAPK1 4620/4885KMT2A 4069/4885SMN1; SMN2 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.